China’s First ADC Secures Domestic Approval
Gastric Cancer Nod
RemeGen’s second approval after a green light for its lupus drug signals accelerating approvals for domestically-developed antibodies in China.
You may also be interested in...
Japan approves a batch of new products and indications, including Daiichi Sankyo's Enhertu in a high-need indication after a rapid review and Takeda's Zejula, which will be made available to selected patients before its reimbursement listing.
After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.
The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.